ClinicalTrials.gg

Program

valemetostat

Its studies are mostly in Prostatic Neoplasms, led by Daiichi Sankyo.

Furthest: phase 1, since Nov 17, 20251 company-led study, 1 open or runningNext primary completion: Jan 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo11 open or runningphase 1since Nov 17, 2025Nov 17, 2025Jan 31, 2028phase 1 · NCT07244341

Also a collaborator on its studies: Bayer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2025First study: phase 1 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT07244341 · 60 planned · United States, Australia, China and more

Ahead

  1. Jan 31, 2028Primary completion: phase 1 study in Metastatic Castration-resistant Prostate CancerNCT07244341

TargetBeta

EZH1 →EZH2 →read by rule
“An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07244341Metastatic Castration-resistant Prostate Cancer · United States, Australia, China and more1RecruitingJan 31, 202860

How it is read

Names in the registry

  • “Valemetostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.